What is Intrapace?
Intrapace is focused on developing innovative solutions for gastrointestinal disorders, including Crohn's disease and ulcerative colitis. The company's technological advancements span diagnostics for Inflammatory Bowel Disease (IBD), sensing capabilities for inflammation and ischemia, localized drug delivery systems, and surgical marking tools. This positions Intrapace as a key player in the gastrointestinal therapeutics and medical device sector.
How much funding has Intrapace raised?
Intrapace has raised a total of $129.3M across 5 funding rounds:
Unspecified
$116.9M
Unspecified
$6.2M
Multiple Rounds
$6.2M
Unspecified (2010): $116.9M, investors not publicly disclosed
Unspecified (2012): $6.2M, investors not publicly disclosed
Debt (2013): $624K, investors not publicly disclosed
Unspecified (2013): $2.2M, investors not publicly disclosed
Unspecified (2013): $3.3M, investors not publicly disclosed
What's next for Intrapace?
The substantial enterprise-level funding and recent strategic investment indicate a pivotal growth phase for Intrapace. This capital infusion is likely earmarked for advancing its novel treatment pipelines, scaling manufacturing capabilities, and expanding its market reach. The company's focus on integrated diagnostic and therapeutic solutions suggests a strategy aimed at comprehensive patient care within the complex field of gastrointestinal health. Future developments may include clinical trial advancements and strategic partnerships to bring its innovations to a wider patient population.
See full Intrapace company page
